Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mirdametinib, a methyl ethyl ketone (MEK) inhibitor, works by blocking the action of an abnormal protein that signals cancer cells to multiply. This may help slow or stop the spread of cancer cells. Giving mirdametinib may be effective in treating patients with relapsed or refractory CLL or SLL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma potwierdzoną diagnozę przewlekłej białaczki limfocytowej (CLL) lub małego chłoniaka limfocytowego (SLL).
- •U pacjenta stwierdzono potrzebę leczenia zgodnie z wytycznymi (np. powiększona śledziona/węzły chłonne, znaczne zmęczenie, utrata wagi, gorączka/poty nocne, szybki wzrost liczby białych krwinek, problemy ze szpikiem kostnym).
- •Choroba pacjenta jest mierzalna (np. określona liczba białych krwinek, wyczuwalne lub widoczne w badaniach obrazowych powiększone węzły chłonne, naciek szpiku kostnego).
- •Pacjent otrzymał co najmniej dwie wcześniejsze terapie na CLL, w tym leki hamujące kinazę Brutona (BTK) i BCL2.
- •Pacjent ma co najmniej 18 lat.
✗ Disqualifies
- •Pacjent nie spełnia kryteriów kwalifikacji.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 31, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
City of Hope Comprehensive Cancer Center
Duarte, United States
City of Hope at Irvine Lennar
Irvine, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
Dana-Farber Cancer Institute
Boston, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, United States
Trial contact
Site Public Contact
Benjamin M. Heyman
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Sheila Firoozan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jennifer R. Brown
PRINCIPAL_INVESTIGATOR
Site Public Contact
Deborah M. Stephens
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kerry A. Rogers
PRINCIPAL_INVESTIGATOR
Site Public Contact
John C. Byrd
PRINCIPAL_INVESTIGATOR
Site Public Contact
Margaret K. Baron
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.